



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

4 May 2020

skox@igbamedicines.org

IGBA Pays Tribute to Bill Haddad

IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today pays tribute to Bill Haddadⁱ, who passed away last week. He was a pioneer in the development of generic medicine policy in the U.S.A. and a remarkable advocate for access to medicines worldwide.

“Within the pharmaceutical industry, Bill Haddad will always be remembered and honored for having initiated and negotiated the 1984 Drug Price Competition and Patent Restoration Act (Hatch-Waxman), the legislation in the United States that created the framework for generic medicines thereby introducing competition in the industry”, commented Hanan Sboul, IGBA Chair. “These developments inspired generic medicines policies worldwide which strongly support increased access to quality medicines,” she added.

“Bill Haddad spent his life taking care of other people. We will always be grateful to him for his unrelenting efforts to remove the barriers to the use of generic antiretroviral medicines during the HIV/AIDS crisis,” emphasized Suzette Kox, IGBA Secretary General.

ⁱ [BIO William F. Haddad](#) BIO shared by James Love, Ip-health on 1 May 2020

About IGBA

The International Generic and Biosimilar medicines Association (IGBA) was founded to strengthen cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.